TGIF2LX1 inhibitors are a class of chemical compounds specifically designed to target and inhibit the activity of the TGIF2LX1 protein, which is a member of the TGIF (thymine-rich, G-rich, and immunoglobulin-like factors) family. This protein plays a significant role in regulating gene expression and cellular development, particularly in the context of embryonic development and patterning. TGIF2LX1 acts as a transcriptional co-repressor, modulating the activity of various transcription factors by binding to their target genes. Inhibition of TGIF2LX1 is achieved primarily by binding to its critical regions, such as the DNA-binding domain or interaction sites essential for recruiting other proteins involved in transcriptional regulation. By occupying these binding sites, TGIF2LX1 inhibitors effectively disrupt the protein's normal regulatory functions, leading to altered gene expression profiles. Some inhibitors may also function through allosteric mechanisms, binding to regions separate from the active site and inducing conformational changes that diminish the protein's activity. The binding interactions between these inhibitors and TGIF2LX1 are typically stabilized by a range of non-covalent forces, including hydrogen bonds, hydrophobic interactions, van der Waals forces, and ionic interactions.
Structurally, TGIF2LX1 inhibitors demonstrate considerable diversity, enabling specific interactions with different regions of the TGIF2LX1 protein. These inhibitors often incorporate functional groups such as hydroxyl, carboxyl, or amine groups, facilitating strong interactions through hydrogen bonding and ionic interactions with key amino acid residues in the protein's binding pockets. Many TGIF2LX1 inhibitors also feature aromatic rings or heterocyclic structures that enhance hydrophobic interactions with non-polar regions of the protein, thereby contributing to the overall stability of the inhibitor-protein complex. The physicochemical properties of TGIF2LX1 inhibitors, including molecular weight, solubility, lipophilicity, and polarity, are meticulously optimized to ensure effective binding and stability in various biological environments. This balance between hydrophilic and hydrophobic regions allows TGIF2LX1 inhibitors to interact selectively with both polar and non-polar areas of the protein, ensuring robust and efficient inhibition of TGIF2LX1 activity across diverse cellular contexts.
Siehe auch...
| Produkt | CAS # | Katalog # | Menge | Preis | Referenzen | Bewertung |
|---|---|---|---|---|---|---|
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $105.00 $153.00 | 4 | |
Als TGF-β-Rezeptor-Kinase-Inhibitor könnte LY364947 die TGIF2LX-Expression reduzieren, indem es die Aktivierung seiner Signalkaskade behindert. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $209.00 $352.00 | 3 | |
Dieser selektive Inhibitor des TGF-β-Rezeptors I kann möglicherweise die TGIF2LX-Expression unterdrücken, indem er die TGF-β-vermittelte Transkriptionsaktivierung hemmt. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $75.00 $150.00 $215.00 $650.00 $1224.00 $4296.00 $7818.00 | 8 | |
RepSox ist ein selektiver Inhibitor des TGF-β-Rezeptors, der die TGIF2LX-Expression durch Abschwächung der TGF-β-Signalübertragung vermindern könnte. | ||||||
Pirfenidone | 53179-13-8 | sc-203663 sc-203663A | 10 mg 50 mg | $100.00 $408.00 | 6 | |
Dieses kleine Molekül könnte indirekt die TGIF2LX-Expression verringern, indem es TGF-β-vermittelte fibrogene Reaktionen moduliert. | ||||||
Halofuginone | 55837-20-2 | sc-507290 | 100 mg | $1740.00 | ||
Halofuginon hemmt die TGF-β-Signalübertragung, was möglicherweise zu einer verringerten TGIF2LX-Expression führt, indem es die Regulierung der nachgeschalteten Gene stört. | ||||||
Tranilast | 53902-12-8 | sc-200389 sc-200389A sc-200389B sc-200389C | 10 mg 50 mg 1 g 5 g | $30.00 $101.00 $277.00 $959.00 | 2 | |
Tranilast könnte die TGIF2LX-Expression hemmen, indem es TGF-β antagonisiert und die damit verbundene Transkriptionsaktivität reduziert. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $86.00 | 3 | |
Als TGF-β-Rezeptor-I-Kinase-Inhibitor konnte SD-208 die TGIF2LX-Expression durch Blockierung des TGF-β-Signalwegs herunterregulieren. | ||||||
EW-7197 | 1352608-82-2 | sc-507465 | 5 mg | $345.00 | ||
EW-7197 hemmt die TGF-β-Signalübertragung, was zu einer verringerten Expression von TGIF2LX führen könnte, indem es in die Induktionsmechanismen eingreift. | ||||||
LY2109761 | 700874-71-1 | sc-396262 sc-396262A | 1 mg 5 mg | $87.00 $270.00 | 9 | |
Diese Chemikalie kann die TGIF2LX-Expression verringern, indem sie die Kinaseaktivität des TGF-β-Rezeptors I hemmt und damit dessen Signalweg blockiert. | ||||||
Ceralasertib | 1352226-88-0 | sc-507439 | 10 mg | $573.00 | ||
Vactosertib könnte durch Hemmung des TGF-β-Rezeptors I die Expression von TGIF2LX durch Unterdrückung seines Signalweges verringern. | ||||||